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| INTRODUC TI ON
Bladder cancer (BC) is one of the most common malignant epithelial tumors, causing an estimated 429 800 new cases and 165 100 deaths in 2012 worldwide. 1 At the initial diagnosis, approximately 30% of cases are diagnosed as muscle-invasive bladder cancer (MIBC), which frequently leads to local invasion and distant metastasis. Patients with MIBC have a poor prognosis, and the 5-year survival rates for locally advanced and metastatic MIBCs are less than 35% and 5%, respectively. 2 The remaining 70% of cases are diagnosed as non-muscle invasive bladder cancer (NMIBC). Although the 5-year survival rate for NMIBC is more than 90%, 50-70% of NMIBC patients are highly relapsed, and 10-20% of these patients progress to MIBC. [3] [4] [5] [6] Radical cystectomy has been considered as the standard cura- for M-VAC and 14.0 months for GC. 7 However, these regimens frequently produce serious side-effects in some BC patients, making it impossible for them to continue. Moreover, tumors treated with these regimens ultimately acquire platinum resistance. Therefore, in the past 30 years, there has been no standard second-line therapy following these cisplatin-based combination chemotherapies. Molecular targeted therapy is anticipated to become one appropriate treatment for selected BC patients. The Cancer Genome Atlas (TCGA) Research Network has suggested the presence of potential therapeutic targets in 69% of BC patients, including 42% with targets in the PI3K/AKT/ mTOR pathway and 45% with targets in the receptor tyrosine kinase (RTK)/MAPK pathway. 8 However, none of these molecular targeted therapies have yet been widely accepted in routine clinical practice. Therefore, the development of new molecular targeted treatment strategies is urgently required to improve outcomes for BC patients.
Recently, exosomes have attracted attention as important mediators of intercellular communication. Exosomes contain significant amounts of proteins, nucleic acids, and transcription factors from the cell of origin. [9] [10] [11] [12] In the extracellular environment, these functional biomolecules are stably protected from external degrading enzymes by a lipid bilayer of exosomal membrane. 13 Thus, exosomes play an important role in the horizontal transfer of this proteomic and genetic information to target cells. 14 Several reports have shown that tumor-derived exosomes can facilitate tumor progression and metastasis. 10, 11, 15, 16 Melanoma-derived exosomes induce cancer cell recruitment, ECM deposition, and vascular proliferation in lymph nodes in preparation for metastasis. 17 In addition, metastatic melanoma-derived exosomes induce vascular leakiness, inflammation, and bone marrow progenitor cell recruitment in premetastatic niches, contributing to the formation of distant metastases. 18 Costa-Silva et al reported the sequential steps for liver premetastatic niches by exosomal migration inhibitory factor derived from pancreatic cancer. 19 The expression patterns of exosomal integrins might be useful to predict the metastatic propensity and organ sites of future metastasis. 20 In BC, exosomal EDIL-3 protein from invasive BC cells promotes tumor angiogenesis, cell migration, and invasiveness in vitro, and exosomal EDIL-3 isolated from the urine can successfully distinguish BC patients from healthy controls as a biomarker. 21 Furthermore, exosomes isolated from BC patient urine induce epithelial-mesenchymal transition in recipient cells. 22 These results suggest that BC-derived exosomes can transform recipient cells to facilitate tumor progression. Thus, it is necessary to clarify the further exosomal role in the formation of distant metastases in BC to establish effective treatment strategies.
The v-Crk (CT10 regulator of kinase) protein was originally isolated as the oncogene fusion product of the CT10 retrovirus in chicken fibrosarcomas. 23 Cellular homologues of v-Crk encode 2 alternatively spliced isoforms (CRK-I and CRK-II) and the related protein (CRKL). 24, 25 CRK-I contains an Src homology (SH) 2 domain and an SH3 domain, whereas CRK-II has an additional SH3 domain at the C-terminus and a linker region (Y221) between 2 SH3 domains.
CRK has been well known as an adaptor protein that mediates the receptor of tyrosine kinase and small G-protein interactions. CRK lacks enzymatic activity, but it plays a crucial role in cellular functions including cell growth, migration, adhesion, and invasion. 26, 27 Overexpression of CRK has been identified in various human cancers.
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We have previously reported that CRK is overexpressed in BC and induces epithelial-mesenchymal transition, contributing to the formation of metastasis. 35 However, the relationship between CRK and exosomes has remained unknown. In this study, we describe a novel role of exosomal ErbB2 regulated by CRK in the process of tumor progression and metastasis in human invasive BC.
| MATERIAL S AND ME THODS

| Cell lines and establishment of BC lines stably expressing tdTomato-Luc2 and Crk knockdown BC cells
The human BC cell lines UM-UC-3, J82, TCC-SUP, T24, and 5637 cells were purchased from ATCC (Manassas, VA, USA) and stably transfected with pCSII-CMV-tdTomato-Luc2 as described previously. 35 UM-UC-3 and J82 cells were also transfected with a plasmid producing siRNAs for CRK as described previously. 36 The HUVECs were from Riken Cell Bank (Tsukuba, Japan). The detailed culture conditions are described in Appendix S1.
| Exosome purification and fluorescent labeling
Fetal bovine serum was ultracentrifuged at 110 000 g for 2 hours for depletion of exosomes in bovine serum, so-called exosome-depleted FBS. Exosomes of human BC cell lines were purified by sequential centrifugation as previously described with minor modifications. 18, 20 Purified exosomes were fluorescently labeled using PKH67 green membrane dye (Sigma-Aldrich, St. Louis, MO, USA). 37 The detailed methods were described in Appendix S1.
| Uptake and internalization of exosomes in vitro
For in vitro exosome uptake assays, 5637 cells or HUVECs (1 × 10 5 )
were incubated with 20 μg PKH67-labeled exosomes derived from UM-UC-3 cells for 24, 48, and 72 hours. Cellular uptake and internalization of the exosomes were observed under a fluorescence microscope. As a control, the membranes of 5637 cells and HUVECs were directly labeled with PKH67 dye, according to the protocol provided by the manufacturer.
| RNA extraction and gene expression analysis
Total RNAs of BC cells and exosomes were extracted using the RNeasy Mini kit (Qiagen, Valencia, CA, USA), whereas microRNA was using the mirVana miRNA Isolation Kit. cDNA was synthesized using Superscript ViLo (Invitrogen, Carlsbad, CA, USA), and quantitative RT-PCR was undertaken using the StepOne real-time PCR system (Applied Biosystems, Foster City, CA, USA) as described previously. 38 The sequences of the primers are listed in Table S1 .
The relative expression levels of total RNA and microRNA to control samples were normalized to GAPDH and RNU6B levels, respectively.
| Immunoblotting analysis and Abs
Immunoblot analyses were carried out as described previously. 
| Mass spectrometry analysis
| Proliferation assay
For the proliferation analysis of cells treated with exosomes, 5637 cells (1 × 10 5 ) and HUVECs (2 × 10 4 ) were treated with UM-UC-3
cell-derived exosomes. The numbers of cells were counted using a cell counter after 48, 96, and 144 hours.
| Matrigel invasion assay and chemotaxis assay
The 5637 cells were pretreated with UM-UC-3 cell-derived exosomes for 48 hours, and the Matrigel invasion assay was carried out as described previously. 
| Orthotopic xenograft mouse model and bioluminescent imaging
All animal studies were carried out in accordance with the protocol approved by the Institutional Animal Care and Use Committee at Hokkaido University Faculty of Medicine. We have previously reported the methods for the orthotopic xenograft models of bladder cancer cells. 35 After the primary and metastatic tumors were identified by the IVIS Spectrum imaging system (Caliper Life Sciences, Hopkinton, MA, USA), 35 they were excised and isolated.
| Education of mice with exosomes and in vivo tracking
Six-week-old BALB/cAJcl nu/nu female mice and NOD/ShiJic-scid Jcl mice (CLEA Japan, Tokyo, Japan) were used for the exosome education studies. Ten micrograms of PKH67-labeled exosomes was i.v. injected every other day for 2 weeks as described previously.
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The mice were divided into 3 groups: Empty-exos group, CRKi-exos group, and PBS injected group as control. UM-UC-3 parent cells
(1 × 10 6 ) labeled with tdTomato-Luc2 were injected into the tail vein. After 24 hours, the tumor cells were detected using the IVIS Spectrum system, and the targeted organs were excised. The distribution of PKH67-labeled exosomes and tdTomato-expressing UM-UC-3 cells in the targeted organs was analyzed under a fluorescence microscope. For histological analysis, the tissues were sectioned and stained with H&E.
| Detection of lung metastasis in exosomeeducated mice
After the exosome-educated mice were injected with tumor cells as described above, the metastatic formation was traced using the IVIS system. 35 After the metastatic tumors were identified, the metastatic organs were excised and analyzed under a fluorescence microscope. The tissues were also utilized for histological H&E staining and MIB-1 staining.
| In vitro vascular permeability assay
The in vitro vascular permeability assay was carried out using a 
| Statistical analysis
Graphical data are presented as the mean and SD. Student's t test or the Mann-Whitney U test was chosen to analyze significant differences. P < .05 and P < .01 were considered as significant and highly significant, respectively. JMP version 10 (SAS Institute, Cary, NC, USA) was used for all statistical analyses. Figure 1D ). In UM-UC-3-injected mice, tissues of primary bladder tumors and metastases to lung, liver, and bone were resected, and tumor cells with tdTomato fluorescence could be isolated ( Figure 1E ). Based on these malignant features, the UM-UC-3 cells were used for further investigations of the metastatic progression of BC.
| RE SULTS
| UM-UC-3 BC cells with high expression of CRK promote invasiveness and metastasis in vivo
| CRK-depleted BC cells suppress tumor progression and metastasis through a decrease in ErbB2 and ErbB3 expression
To 
| Exosomes derived from invasive BC contain ErbB2 through CRK regulation
To investigate a participation of exosomes in CRK-regulated malignant features of invasive BC, exosomes were isolated from conditioned Tumor growth was monitored weekly using the IVIS Spectrum imaging system. E, After 35 days, the UM-UC-3-injected mice were killed, and bioluminescent imaging photons from primary bladder tumor and liver-and lung-metastatic tumor burden were obtained ex vivo (left).
Fluorescence microscopy showed tdTomato-expressing tumor cells isolated in the culture dish (right) medium of UM-UC-3 cells with or without CRK. Mass spectrometry analysis was carried out to identify proteins that were downregulated in exosomes by CRK depletion ( Figure 3A , Emp-1 vs Crki-1), and many proteins, including EGFR, ErbB2, EPHA2, EPHB4, Src, integrin α2, and integrin α3, were nominated (Table S2 ). ErbB2 and integrin α2, also likely ErbB3 and FAK, seem to be declined in CRKi exosomes (CRKi-exos)
( Figures 3B and S2A ). In contrast, expression levels of EPHA2, EPHA4, EPHB4, and integrin α3 remained unchanged, irrespective of CRK expression ( Figure S2A ). CRK has no effect on expression of mRNAs of RTKs and their ligands, and RTK-related microRNAs in exosomes ( Figure S2B-D) . It is noteworthy that we were able to detect a considerable amount of CRK-II protein in exosomes from parental and control Figure 4D ). Phosphorylation levels of FAK, Src, AKT, EGFR, and cMET seemed to decline followed by treatment with CRK-depleted exosomes ( Figures 4D and S3C ). In contrast, there were no differences in mRNA expression levels of RTKs and their ligands, or in RTK-related microRNAs, in 5637 cells treated with or without CRK ( Figure S3D-F) .
| Human umbilical vascular endothelial cells promote cell proliferation and invasion through exosomes derived from high-grade BC
To further determine the role of BC-derived exosomes on tumor angio- Furthermore, the expression levels of ErbB2, ErbB3, and CRK-II and the phosphorylation levels of FAK and AKT increased following treatment with parent and Empty-exos, but CRKi-exos had no effect ( Figures 5D and S4 ).
F I G U R E 2 Depletion of CRK decreases expression of ErbB2 and ErbB3 in bladder cancer cells and abolishes metastasis of bladder cancer in vivo. A, Establishment of CRK knockdown bladder cancer cells. UM-UC-3 cells were stably transfected with expression plasmids producing shRNA targeting CRK (CRKi) or its control vector (Empty). Cell lysates of parent, control (Empty)
, and CRK knockdown cells (CRKi) were subjected to immunoblotting with anti-CRK and CRK-L Abs. α-Tubulin was used as a loading control. Photomicrographs of the cells were obtained under bright-field illumination (right panels). B,C, tdTomato-luc2-labeled UM-UC-3 cells (parent, empty, and CRKi) were injected into the bladder muscle layer in athymic mice (n = 4, each group). Tumor growth was measured weekly using the IVIS Spectrum imaging system (B) and graphed as the mean ± SD (C). In CRKi cell-injected mice, metastasis to the liver and lung was absent. D, Total RNAs were isolated from UM-UC-3 cells (parent, empty, and CRKi), and endogenous expression levels of EGFR, cMET, ErbB2, and ErbB3 mRNAs were analyzed by quantitative RT-PCR. E,F, Levels of expression and phosphorylation of epidermal growth factor receptor (EGFR), cMET, ErbB2, and ErbB3 (E) and CRK-related signaling molecules (F) were examined by immunoblotting Photomicrographs of the cells were obtained under bright-field illumination (left) and using a fluorescence microscope (middle). B, Proliferation of HUVECs treated with exosomes derived from UM-UC-3 cells (parent, empty, and CRKi) (red arrow) were counted under a microscope at the indicated time points and expressed as the mean ± SD of 3 independent experiments. Cells treated with PBS were used as a control (exos (-)). **P < .01. C, Migration of HUVECs treated with exosomes derived from UM-UC-3 cells with or without CRK were analyzed by chemotactic assay. The cells migrating through the filter were counted and depicted as the mean ± SD. **P < 0.01. D, In HUVECs treated without or with UM-UC-3-derived exosomes (parent, empty, and CRKi), levels of expression and phosphorylation of the indicated proteins were investigated by immunoblotting
In another xenograft setting, we investigated the metastatic progression of BC cells after exosome education. After education for 2 weeks, tdTomato-Luc2-expressing UM-UC-3 cells were injected into nude mice as described above, and metastatic progression was evaluated using the IVIS Spectrum system every week ( Figure 6C ). Six weeks later, metastases to the lung and lower abdomen were detected only in the mice educated with Emp-exos ( Figure 6C ) and were confirmed under a fluorescence microscope and by histological examination ( Figure 6D ). Similar results were obtained in NOD-Scid mice at an earlier phase ( Figure 6E,F) . Of note, in lung metastatic tumors educated with Emp-exos, vascular invasion and angiogenesis were clearly promoted with a disturbed pulmonary alveolus ( Figures 6G and   S5 ). Supporting this data, the permeability of the vascular sheet formed by HUVECs increased to 1.57-and 1.53-fold following treatment with parent-and Empty1-exos, respectively, relative to HUVECs without exosomes, whereas Crki1-exos had no effect (1.08-fold; Figure 6H ). 
| D ISCUSS I ON
Invasive BC with advanced progression and distant metastasis has shown a poor prognosis in the past 30 years. Therefore, it is an urgent issue to reveal the underlying mechanisms of tumor progression and metastasis to develop new treatment strategies for BC patients.
In the present study, we unveiled a novel function of CRK/ErbB2 through exosomes; this function plays an important role in tumor progression and metastatic formation in invasive BC. could also be a potential therapeutic target in 6% of BC, 8 and both
ErbB2 and ErbB3 tended to be associated with a poor prognosis in BC patients. 50 In the present study, we showed that CRK is a key regulator of ErbB2/3 expression and CRK-mediated ErbB2/3 elevation in exosomes contributed to the metastatic progression of BC. Therefore, CRK intervention could be a powerful treatment strategy to suppress metastasis of BC by complete blockage of ErbB2/3 signaling.
Tumor-derived exosomes have protumorigenic roles, and oncogenic RTKs are present in exosomes. Peinado et al 18 showed that exosomes are able to horizontally transfer MET from melanoma to bone marrow progenitor cells to educate them toward a prometastatic phenotype. Exosomes derived from glioma cells have been shown to contribute to the horizontal transfer of oncogenic EGFRvIII. 15 However, the role of exosomes in tumor progression and metastasis of BC has remained unclear. Here, we found that ErbB2 proteins are contained in invasive BC-derived F I G U R E 6 Education of the metastatic target organ with high-grade bladder cancer-derived exosomes (exos) facilitate metastasis in vivo. A, Mice were divided into 3 groups: Emp-exos group, CRKi-exos group, and PBS-injected group as a control. PKH67-labeled exosomes (10 μg Emp-exos or CRKi-exos) or PBS were injected i.v. in athymic nude mice every other day for 2 weeks. After exosome education, UM-UC-3 parent cells (1 × 10 6 cells) were injected into the tail vein. After 24 h, the tumor cells trapped in lung were detected using the IVIS Spectrum system. B, In lung tissue displayed in (A), the biodistribution of PKH67-labeled exosomes and tdTomato-expressing UM-UC-3 cells were analyzed under a fluorescence microscope. C,E, After exosome education as described in (A), UM-UC-3 cells (1 × 10 6 cells) were injected in BALB/cAJclnu/nu mice (C) and NOD/ShiJic-scid Jcl mice (E) into the tail vein (n = 3, each group). Metastatic formations were tracked using the IVIS system. When the metastatic tumors were identified, the lung tissues were excised. D,F, Lung metastases were confirmed using a fluorescence microscope and histological examination such as H&E staining and immunostaining for MIB-1. G, Resected lung tissues were subjected to immunostaining for CD31. H, HUVECs were treated with or without 20 μg exosomes (parent, Emp-1, and CRKi-1) for 24 h. After FITC-Dextran was added, vascular permeability was measured at 485 nm excitation, 520 nm emission. *P < .0005 exosomes in a CRK-dependent manner ( Figure 3B ) and transferred to the recipient cells ( Figures 4D and 5D ). Wolfers et al 63 showed
that some tumors secreted exosome-like microvesicles containing many proteins, including ErbB2. Ascites-exosomes purified from patients with ovarian and breast cancer include tumor-specific proteins such as ErbB2. 64 Furthermore, human breast cancer cells cultured with tumor-derived exosomes containing highly ErbB2 proteins increased tumor cell proliferation. 65 Thus, invasive BC- and PI3K/Akt activation. 66 The exosomes from glioma stimulated EGFRvIII transfer and activated downstream signaling pathways such as MAPK and AKT cascades in recipient cells. 15 Recently, BC-derived exosomes were reported to activate the Akt and ERK pathways to induce cell proliferation. 67 Taken together, we showed that CRK and ErbB2 in BC-derived exosomes act as key regulators of cellular transformation within premetastatic niches containing endothelial cells and fibroblasts, through FAK and PI3K/AKT signaling activation, in addition to increases in tumor cell proliferation and invasion.
In conclusion, we herein report that CRK elevates the expression of ErbB2/3 in BC cells, and these oncoproteins are transferred to the recipient cells in target organs by exosomes, contributing to the distant metastasis of BC. Thus, we propose that CRK intervention could be a powerful treatment strategy for patients with ErbB2 overexpressing advanced and metastatic BC.
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